South Korea · Delayed Price · Currency is KRW BioNote Statistics
Total Valuation
BioNote has a market cap or net worth of KRW 508.83 billion. The enterprise value is 172.67 billion.
| Market Cap | 508.83B |
| Enterprise Value | 172.67B |
Important Dates
The next estimated earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
BioNote has 101.36 million shares outstanding. The number of shares has decreased by -0.79% in one year.
| Current Share Class | 101.36M |
| Shares Outstanding | 101.36M |
| Shares Change (YoY) | -0.79% |
| Shares Change (QoQ) | -0.38% |
| Owned by Insiders (%) | 58.70% |
| Owned by Institutions (%) | 0.25% |
| Float | 13.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.30 |
| PB Ratio | 0.34 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | 81.15 |
| P/OCF Ratio | 35.38 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.63, with an EV/FCF ratio of 27.54.
| EV / Earnings | -1.97 |
| EV / Sales | 1.46 |
| EV / EBITDA | 6.63 |
| EV / EBIT | 10.27 |
| EV / FCF | 27.54 |
Financial Position
The company has a current ratio of 31.01, with a Debt / Equity ratio of 0.00.
| Current Ratio | 31.01 |
| Quick Ratio | 28.69 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.58 |
| Interest Coverage | 58.54 |
Financial Efficiency
Return on equity (ROE) is -5.56% and return on invested capital (ROIC) is 1.33%.
| Return on Equity (ROE) | -5.56% |
| Return on Assets (ROA) | 0.65% |
| Return on Invested Capital (ROIC) | 1.33% |
| Return on Capital Employed (ROCE) | 1.09% |
| Weighted Average Cost of Capital (WACC) | 8.73% |
| Revenue Per Employee | 397.06M |
| Profits Per Employee | -293.62M |
| Employee Count | 298 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 2.00 |
Taxes
| Income Tax | -70.26M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.12% in the last 52 weeks. The beta is 0.82, so BioNote's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +8.12% |
| 50-Day Moving Average | 5,508.10 |
| 200-Day Moving Average | 5,508.93 |
| Relative Strength Index (RSI) | 37.06 |
| Average Volume (20 Days) | 87,127 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNote had revenue of KRW 118.32 billion and -87.50 billion in losses. Loss per share was -865.00.
| Revenue | 118.32B |
| Gross Profit | 65.68B |
| Operating Income | 16.81B |
| Pretax Income | -87.57B |
| Net Income | -87.50B |
| EBITDA | 26.04B |
| EBIT | 16.81B |
| Loss Per Share | -865.00 |
Balance Sheet
The company has 339.81 billion in cash and 3.65 billion in debt, with a net cash position of 336.16 billion or 3,316.47 per share.
| Cash & Cash Equivalents | 339.81B |
| Total Debt | 3.65B |
| Net Cash | 336.16B |
| Net Cash Per Share | 3,316.47 |
| Equity (Book Value) | 1.51T |
| Book Value Per Share | 14,987.86 |
| Working Capital | 393.71B |
Cash Flow
In the last 12 months, operating cash flow was 14.38 billion and capital expenditures -8.11 billion, giving a free cash flow of 6.27 billion.
| Operating Cash Flow | 14.38B |
| Capital Expenditures | -8.11B |
| Depreciation & Amortization | 9.23B |
| Net Borrowing | -1.28B |
| Free Cash Flow | 6.27B |
| FCF Per Share | 61.86 |
Margins
Gross margin is 55.50%, with operating and profit margins of 14.21% and -73.95%.
| Gross Margin | 55.50% |
| Operating Margin | 14.21% |
| Pretax Margin | -74.01% |
| Profit Margin | -73.95% |
| EBITDA Margin | 22.00% |
| EBIT Margin | 14.21% |
| FCF Margin | 5.30% |
Dividends & Yields
This stock pays an annual dividend of 200.00, which amounts to a dividend yield of 4.00%.
| Dividend Per Share | 200.00 |
| Dividend Yield | 4.00% |
| Dividend Growth (YoY) | 14.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.79% |
| Shareholder Yield | 4.79% |
| Earnings Yield | -17.20% |
| FCF Yield | 1.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNote has an Altman Z-Score of 8.72 and a Piotroski F-Score of 6.
| Altman Z-Score | 8.72 |
| Piotroski F-Score | 6 |